← SynDRA
PALMITINE
SynDRA canonical compound SYN0006123 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | ACHE | CYP3A4 |
|---|
| Mechanism of action | dopamine synthesis inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- dopamine synthesis inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- EP300
- BAZ2B
- KDM1A
- TDP1
- TARDBP
- SLCO1B3
- SLCO1B1
- SLC47A2
- SLC47A1
- RAD52
- RAC1
- P2RX7
- MAPT
- MAPK1
- LMNA
- KDM4E
- HIF1A
- BCHE
- HDAC6
- GSK3B
- GNAS
- GMNN
- FEN1
- ESR1
- CYP2D6
- CYP2C9
- CYP2C19
- CYP1A2
- COPS5
- CDC42
- USP1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ACES
- ADRB2
- ANDR
- ATRX
- CP1A2
- CP2CJ
- CP2D6
- ESRRA
- HCRTR1
- SC5A7
Cross-references
Synonyms
- palmatine-chloride
- Palmatine
- Berbericinine
- O,O-Dimethyldemethyleneberberine
- 5,6-Dihydro-2,3,9,10-tetramethoxydibenzo[a,g]quinolizinium
- palmatine ion
- palmatine cation
- 7,8,13,13a-Tetrahydro-2,3,9,10-tetramethoxyberbinium
- G50C034217
- 5,6-Dihydro-2,3,9,10-tetramethoxydibenzo(a,g)quinolizinium
- CHEBI:16096
- RefChem:44890
- DTXCID0028036
- Palmatin
- Burasaine
- GNF-PF-4086
- MFCD00221758
- 5,6-Dihydro-2,3,9,10-tetramethoxy-dibenzo[a,g]quinolizinium
- BRN 1555498
- SR-01000841226
- C21H22NO4
- Palmatine Chloride
- UNII-G50C034217
- 7,8,13,13a-tetradehydro-2,3,9,10-tetramethoxyberbinium
- Spectrum_001849
- SpecPlus_000619
- SpecPlus_000738
- PALMATINE [MI]
- Prestwick0_000579
- Prestwick1_000579
- Prestwick2_000579
- Prestwick3_000579
- Spectrum2_000608
- Spectrum3_000907
- Spectrum4_001005
- Spectrum5_000684
- Spectrum5_001860
- PALMATINE [WHO-DD]
- BSPBio_000398
Look up PALMITINE in the interactive SynDRA portal →